May 2025 FDA Recall Ezetimibe And Simvastatin by Glenmark Pharmaceuticals Inc., Usa
D-0462-2025 - Failed Impurities/Degradation Specifications

This Class III drug recall was voluntarily initiated by Glenmark Pharmaceuticals Inc., Usa on May 19, 2025 for the product Ezetimibe And Simvastatin. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0462-2025

Reason for Recall
Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study.
Initiated
05-19-2025
Reported
06-18-2025
Quantity
6,759 Con - 90 bottle pack

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Glenmark Pharmaceuticals Inc., USA
Nationwide USA and PR
Ezetimibe and Simvastatin Tablets, 10mg/40mg, 90-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Madya Pradesh, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-323-90

Batch or Lot Expiration Information

Lot# : 17240195, Exp 01/31/2026.